TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

Abstract

<i>TP53</i> mutations reduce responsiveness to crizotinib and worsen prognosis in <i>ALK</i> rearrangement NSCLC patients.